Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?
Open Access
- 11 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Current Molecular Biology Reports
- Vol. 6 (1), 1-9
- https://doi.org/10.1007/s40610-020-00126-z
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human diseaseScience Advances, 2019
- Biological Role and Therapeutic Potential of IDH Mutations in CancerCancer Cell, 2018
- Isocitrate dehydrogenase mutations in myeloid malignanciesLeukemia, 2016
- Molecular Pathways: Isocitrate Dehydrogenase Mutations in CancerClinical Cancer Research, 2016
- IDH mutations in cancer and progress toward development of targeted therapeuticsAnnals Of Oncology, 2016
- IDH1andIDH2Mutations in Tumorigenesis: Mechanistic Insights and Clinical PerspectivesClinical Cancer Research, 2012
- The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylasesEMBO Reports, 2011
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2010
- Crystal Structure of the Monomeric Isocitrate Dehydrogenase in the Presence of NADP+Journal of Biological Chemistry, 2003
- Structure of the Monomeric Isocitrate Dehydrogenase: Evidence of a Protein Monomerization by a Domain DuplicationStructure, 2002